

Expert	Type of Relationship with Industry
Adamo Marianna	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Edwards Lifesciences, Abbott Vascular
	2025 Payment from healthcare industry Abbott, Edwards Lifesciences, Medtronic, Roche Diagnostics
Bayes Genis Antoni	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bayer, Boehringer-Ingelheim, Medtronic, Vifor International, Novo-Nordisk, Roche Diagnostics
	2025 Payment from healthcare industry Astra Zeneca, Bayer, Boehringer-Ingelheim, Medtronic, Abbott Laboratories, Novo-Nordisk, Roche Diagnostics
Boehm Michael	2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Medtronic, Novartis, Servier, Vifor International, Bristol Myers Squibb, Cytokinetics
	2025 Payment from healthcare industry Abbott, Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Medtronic, Novartis, Servier, Vifor International, Bristol Myers Squibb, Cytokinetics Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions: Pressspokesman of the German Society of Cardiology Positions as Editor in Chief: No Other editorial positions: Editorial Board Hypertension
Chioncel Ovidiu	2024 Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Boehringer-Ingelheim internal meeting 2 nights accommodation Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Associate Editor: BMC Cardiovascular Disorders Exploration in Medicine Cardiac Failure Review Journal of Acute Disease, Heart Failure Reviews
	2025 Payment from healthcare industry Eli Lilly Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Boehringer-Ingelheim internal meeting 2 nights accommodation

Expert	Type of Relationship with Industry	
Chioncel Ovidiu	2025	<p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:none Positions as Editor in Chief:none Other editorial positions:Associate Editor: BMC Cardiovascular Disorders, Journal of Acute Disease, Heart Failure Reviews; without any financial interest for all of these</p>
Dawson Dana	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity British Heart Foundation, National Institute for Health and Care Research Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Member of the Women's Health Plan for the Scottish Government</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations British Heart Foundation, National Institute for Health and Care Research Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine/sciences Member of the Women's Health Plan for the Scottish Government</p>
Flammer Andreas	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer, Boehringer-Ingelheim, Pfizer, Alnylam Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Alexion</p>
	2025	<p>Payment from healthcare industry Astra Zeneca, Bayer, Pfizer, Alnylam</p>
Hage Camilla	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Heart and Lung foundation, Swedish Research Council, Horizon 2020 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer, Novartis, Roche Diagnostics, Astrazeneca, AnaCardio Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Bayer</p>

Expert	Type of Relationship with Industry	
Hage Camilla	2025	<p>Payment from healthcare industry Abbott, Astrazeneca, AnaCardio</p> <p>Receipt of royalties for intellectual property Studentlitteratur</p>
Linke Wolfgang	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. myriamed, Dewpoint Therapeutics</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Dewpoint Therapeutics</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Dewpoint Therapeutics</p>
	2025	<p>Payment from healthcare industry myriamed, Dewpoint Therapeutics</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Dewpoint Therapeutics</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Dewpoint Therapeutics</p>
Metra Marco	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim, Edwards Lifesciences, Bayer AG, Roche Diagnostics, Abbott Structural Heart</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations EC HORIZON 2020 funded activities for research manager working at my Institute while I was working at the University of Brescia, i.e. until 30 September 2025</p> <p>Payment from healthcare industry Astra Zeneca, Bayer, Boehringer-Ingelheim, Servier, Novo-Nordisk, Zoll Medical, Ely Lilly</p>
Moura Brenda	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bayer, Boehringer-Ingelheim, Vifor Pharma, viatris</p>
	2025	<p>Payment from healthcare industry Boehringer-Ingelheim, Bayer</p>
Mullens Wilfried	2024	Nothing to be declared

Expert	Type of Relationship with Industry	
Mullens Wilfried	2025	Nothing to be declared
Petrie Mark C	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen, Astra Zeneca, Boehringer-Ingelheim, Novartis, Roche Pharma, Roche Diagnostics, Novo Nordisk, AbbiVie, Foundry, Pharmacosmos, Sq Innovations, Corteria, Reprieve, Akero</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Novartis, 3R Biosciences</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Vifor International</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Sq Innovations</p>
	2025	Declaration not submitted
Ponikowski Piotr	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Medical Research Agency</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Pfizer, Servier, Vifor International, Abbott Vascular, Novo-Nordisk, Pharmacosmos</p>
	2025	Declaration not submitted
Rakisheva Amina	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Boehringer-Ingelheim</p>
	2025	<p>Payment from healthcare industry Astra Zeneca, Roche Diagnostics, TMA</p>
Recio Mayoral Alejandro	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Johnson & Johnson, MSD, AOP Orphan Pharmaceuticals</p>
	2025	<p>Payment from healthcare industry Astra Zeneca, Bayer, Boehringer-Ingelheim, Novartis, Johnson & Johnson, Alnylam, MSD, AOP Orphan Pharmaceuticals</p>

Expert	Type of Relationship with Industry
Savarese Gianluigi	<p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott, Astra Zeneca, Boehringer-Ingelheim, Medtronic, Novartis, Servier, Menarini, Vifor International, Novo-Nordisk, Bayer AG, Hikma, INTAS, GETZ</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Novartis</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca, Bayer, Medtronic, Novartis, Servier, Vifor International, Cytokinetics</p> <hr/> <p>2025 Payment from healthcare industry Astra Zeneca, Boehringer-Ingelheim, Medtronic, Novartis, Servier, Menarini, Vifor International, Bayer AG, Labcorp, Laboratori Guidotti</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Astra Zeneca, Medtronic, Novartis, Servier, Vifor International, Viatrix</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position Speaker fees from other companies involved in educational activities (Radcliffe, TMA)</p>
Seferovic Petar	<p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim</p> <hr/> <p>2025 Declaration not submitted</p>
Stoerk Stefan	<p>2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Federal Ministry for Education and Research</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Boehringer-Ingelheim, Novartis, Bayer Healthcare, Novo-Nordisk</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim, Novartis, Bayer Healthcare, Merck Sharp & Dohme, Novo-Nordisk, Amaryn, Ionis, Cytokinetics</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. German Cardiac Society Writing Group German Guidelines Heart Failure Writing Group: Heart Failure Policy Network</p>

Expert	Type of Relationship with Industry
Stoerk Stefan	<p>2025</p> <p>Ongoing research funding from public and/or not-for-profit organisations Federal Ministry for Education and Research</p> <p>Payment from healthcare industry Astra Zeneca, Boehringer-Ingelheim, Novartis, Bayer Healthcare, Novo-Nordisk</p> <p>Payment from healthcare industry to department or institution or any other body for personal services Boehringer-Ingelheim, Novartis, Bayer Healthcare, Merck Sharp & Dohme, Novo-Nordisk, Alnylam, Ionis, Cytokinetics</p>
Ter Maaten Jozine	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity NWO Off Road Grant, NWO Veni</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer, Boehringer-Ingelheim, Roche Diagnostics, Moderna, Reprieve</p> <hr/> <p>2025</p> <p>Ongoing research funding from public and/or not-for-profit organisations NWO Off Road Grant, NWO Veni</p> <p>Payment from healthcare industry to department or institution or any other body for personal services Astra Zeneca, Bayer, Boehringer-Ingelheim, Edwards Lifesciences, Novartis, Roche Diagnostics, Chagai</p> <p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:Co-chair of an upcoming KDIGO guideline Positions as Editor in Chief:- Other editorial positions:Associate editor for JCF Associate editor for Heart Failure Reviews Section editor for JACC Heart Failure</p>
Tschoepe Carsten	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bayer Healthcare, Cardiovascular Therapeutics</p> <hr/> <p>2025</p> <p>Payment from healthcare industry Bayer Healthcare</p>
Van Der Meer Peter	<p>2024</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bayer, Novartis, Vifor International, Novo-Nordisk, Pharmacosmos, Bridge bio</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca, Pfizer, Vifor International, Novo-Nordisk, Pharma Nord</p>

Expert	Type of Relationship with Industry	
Van Der Meer Peter	2024	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). associated editor JACC-cardiooncology</p>
	2025	Declaration not submitted
Van Linthout Sophie	2024	<p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Guest Editor of Circulation Heart Failure since November 2022</p>
	2025	<p>Payment from healthcare industry Bayer, Novo-Nordisk Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Sanofi Aventis Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Other editorial positions: Guest Editor Circulation Heart Failure</p>
Volterrani Maurizio	2024	Nothing to be declared
	2025	<p>Payment from healthcare industry Bayer, Novo-Nordisk</p>
Witte Klaus	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity EU Horizons Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott, Astra Zeneca, Bayer, Medtronic, Cardiac Dimensions, Boehringer Ingelheim Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am associate editor of ESCHF and JCSM.</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations EU Horizons Payment from healthcare industry Abbott, Astra Zeneca, Bayer, Medtronic, Cardiac Dimensions, Boehringer Ingelheim</p>